Key result
The release of the COURAGE trial significantly increased the use of medical therapy rather than revascularization for stable angina from 11.1% to 23.0% (P=0.03).
Why the study?
Did the release of the COURAGE trial change the management of stable angina regarding catheterization referral and revascularization?
Observational (n=332)
No
Did the release of the COURAGE trial change the management of stable angina regarding catheterization referral and revascularization?
Absolute Event Rate: 23% vs 11.1%
p-value: p=0.03
The publication of the COURAGE trial immediately influenced clinical practice by decreasing catheterization referrals and increasing the use of medical therapy over revascularization for stable angina.
No takes yet. Share an insight, caveat, or question.
May support greater medical therapy use in stable angina; leaves open causal effects on referrals in broader settings.
Atwater et al. (2009) conducted an observational in Stable angina (n=332). Post-COURAGE trial publication period vs. Pre-COURAGE trial publication period was evaluated on Treatment with medication rather than percutaneous or surgical revascularization among patients with coronary disease (p=0.03). The release of the COURAGE trial significantly increased the use of medical therapy rather than revascularization for stable angina from 11.1% to 23.0% (P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: